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suspected chikungunya cases as they do dengue because of the 
similarities in symptoms and increased risk for complications in 
dengue patients that are not appropriately managed. Residents 
of and travelers to the tropics can minimize their risk for both 
chikungunya and dengue by taking standard measures to avoid 
mosquito bites.
Chikungunya* is an emerging infectious disease character-
ized by fever and arthralgia (2). After the first locally acquired 
chikungunya case was reported from St. Martin in December 
2013, CHIKV spread rapidly throughout the Americas, with 
nearly 1 million cases reported to date.† Both CHIKV and 
the four dengue viruses (DENV-1–4) are transmitted by Aedes 
aegypti and Aedes albopictus mosquitoes. Dengue§ is endemic 
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Chikungunya and dengue are mosquito-borne, viral, acute 
febrile illnesses that can be difficult to distinguish clinically. 
Whereas dengue is endemic in many countries in the Caribbean 
and the Americas, the first locally acquired chikungunya case 
in the Western Hemisphere was reported from the Caribbean 
island of St. Martin in December 2013 and was soon followed 
by cases in many parts of the region (1). In January 2014, 
the Puerto Rico Department of Health (PRDH) and CDC 
initiated chikungunya surveillance by building on an exist-
ing passive dengue surveillance system. To assess the extent 
of chikungunya in Puerto Rico, the severity of illnesses, and 
the health care–seeking behaviors of residents, PRDH and 
CDC analyzed data from passive surveillance and investiga-
tions conducted around the households of laboratory-positive 
chikungunya patients. Passive surveillance indicated that the 
first locally acquired, laboratory-positive chikungunya case in 
Puerto Rico was in a patient with illness onset on May 5, 2014. 
By August 12, a total of 10,201 suspected chikungunya cases 
(282 per 100,000 residents) had been reported. Specimens 
from 2,910 suspected cases were tested, and 1,975 (68%) were 
positive for chikungunya virus (CHIKV) infection. Four deaths 
were reported. The household investigations found that, of 250 
participants, 70 (28%) tested positive for current or recent 
CHIKV infection, including 59 (84%) who reported illness 
within the preceding 3 months. Of 25 laboratory-positive par-
ticipants that sought medical care, five (20%) were diagnosed 
with chikungunya and two (8%) were reported to PRDH. 
These investigative efforts indicated that chikungunya cases 
were underrecognized and underreported, prompting PRDH 
to conduct information campaigns to increase knowledge of the 
disease among health care professionals and the public. PRDH 
and CDC recommended that health care providers manage 
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in Puerto Rico (3) and throughout the tropics¶ where these 
mosquitoes exist (4), and is characterized by fever, aches and 
pains, leukopenia, and minor bleeding manifestations (e.g., 
petechial and gingival bleeding) (5). Whereas DENV infection 
does not lead to long-lasting cross-protective immunity but 
rather is associated with increased risk for developing severe 
dengue after infection with another DENV, infection with 
CHIKV results in long-lived immunity that protects from 
future illness.
In January 2014, PRDH and CDC initiated chikungunya 
surveillance in Puerto Rico by modifying the existing Passive 
Dengue Surveillance System (PDSS) (3) to include suspected 
chikungunya. Patients for whom a clinician suspected chi-
kungunya as the cause of illness were reported by sending a 
serum specimen along with a dengue case investigation form** 
on which “suspected chikungunya” was indicated. Specimens 
collected within 5 days of illness onset were tested by real-time 
reverse transcription–polymerase chain reaction (rRT-PCR) 
(6) with updated primers to detect current CHIKV infection. 
Specimens collected ≥6 days after illness onset were tested by 
immunoglobulin M capture enzyme-linked immunosorbent 
assay (MAC-ELISA) (7) to detect recent CHIKV infection. 
Specimens from suspected dengue patients and some specimens 
from suspected chikungunya patients were tested by rRT-PCR 
(8) or MAC ELISA to detect current or recent DENV infec-
tion, respectively. Laboratory-positive chikungunya cases 
were defined as suspected chikungunya cases with test results 
indicating current or recent CHIKV infection. 
Epidemiologic and Laboratory Investigation
Passive surveillance analysis. Suspected chikungunya cases 
were first reported in January 2014, and the first laboratory-
positive patient had illness onset on May 5 (Figure 1). The 
patient was a resident of the San Juan metropolitan area and did 
not report travel outside of Puerto Rico in the 14 days before 
illness onset. Additional laboratory-positive chikungunya cases 
were reported in the following weeks from throughout the San 
Juan and Ponce metropolitan areas (Figure 2). By August 12, a 
total of 10,201 suspected chikungunya cases (282 per 100,000 
residents) had been reported from 57 (73%) of Puerto Rico’s 78 
municipalities. Specimens from 2,910 suspected chikungunya 
cases were tested for CHIKV infection, and 1,975 (68%) were 
laboratory-positive. Suspected and laboratory-positive chikun-
gunya cases were reported in all age groups, and incidence was 
highest among persons aged ≥50 years (291 suspected and 57 
laboratory-positive cases per 100,000 residents) (Figure 3).
Of 652 laboratory-positive cases for which demographic and 
clinical information was available, 344 (53%) were in females, 
and the most commonly reported symptoms were fever (87%), 
arthralgia (79%), and myalgia (79%) (Table). Hospitalization 
 ¶ Additional information available at http://www.healthmap.org/dengue/en.
 ** Available at http://www.cdc.gov/dengue/resources/denguecasereports/dcif_
english.pdf.
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FIGURE 1. Week of symptom onset and testing status for suspected chikungunya cases reported to the Puerto Rico Department of Health — 
























FIGURE 2. Geographic distribution of laboratory-positive chikungunya cases, by period and residence — Puerto Rico, May 5–August 12, 2014
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was uncommon (13%), and major bleeding (3%) or severe 
manifestations (2%) were rarely reported. 
Four deaths were reported among laboratory-positive 
chikungunya patients. The first patient was a woman aged 
31 years with coexisting medical conditions (i.e., morbid 
obesity, diabetes, hypothyroidism, and asthma) who was 
brought to the emergency department because of difficulty 
breathing and acute febrile illness. She died within 24 hours 
of hospitalization. The second and third patients were men 
aged 45 and 78 years with preexisting diabetes. Both sought 
care for acute febrile illness, were diagnosed with a localized 
source of bacterial infection that was not confirmed by bacterial 
culture, and died <24 hours and 3 days after hospitalization, 
respectively. The fourth patient was a man aged 57 years with 
a history of congestive heart failure, diabetes, and obesity, who 
was found in his home unresponsive, febrile, and with labored 
breathing. A history of acute febrile illness was obtained, and 
an electrocardiogram revealed evidence of recent myocardial 
infarction. He died <24 hours after hospitalization.
DENV and CHIKV cross-testing. Of 4,433 suspected 
dengue cases reported to PDSS during January 1–August 12, 
426 (9.6%) were laboratory-positive for DENV infection. Of 
147 suspected dengue cases that were laboratory-negative for 
DENV infection and subsequently tested for CHIKV infec-
tion, 21 (14%) were laboratory-positive. Of 761 suspected 
chikungunya cases also tested for DENV infection, 14 (2%) 
were laboratory-positive for DENV infection. Of 908 sus-
pected dengue or chikungunya cases tested for infection with 
both viruses, none were concurrently infected.
Household investigations. Household-based cluster 
investigations were conducted to 1) describe the spectrum of 
disease in CHIKV-infected persons; 2) determine the health 
care–seeking behaviors of persons with chikungunya; and 3) 
determine whether persons with chikungunya who sought 
FIGURE 3. Number of suspected chikungunya cases, by age group* and test status, and number per 100,000 population — Puerto Rico, 
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* Age was available for 9,911 suspected chikungunya cases.
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medical care were appropriately diagnosed and reported. The 
rationale for the design of this investigation was based on 
prior observations that dengue cases cluster within households 
and neighborhoods (9) because of the movement of infected 
mosquitoes and humans (10), whereas human movement 
is the major vehicle for DENV dispersal >100 meters (11). 
Because the same pattern is presumed to be true for CHIKV 
transmission, additional infected persons were expected to be 
found among neighbors of chikungunya patients.
The residences of a convenience sample of reported 
laboratory-positive chikungunya patients were visited, and 
residents of households within a 50-meter radius were offered 
chikungunya diagnostic testing. Participants provided a serum 
specimen and answered a questionnaire regarding household 
characteristics, demographics, travel history, and recent ill-
nesses. Laboratory-positive participants were household inves-
tigation participants with current or recent CHIKV infection.
During June 20–August 19, a total of 21 household inves-
tigations were conducted in the health regions of San Juan 
(nine investigations), Bayamón (eight), Ponce (two), Arecibo 
and Caguas (one each). Of 499 houses visited, 433 (87%) 
were occupied, and an adult was present at the time of visit at 
200 (46%). From these 200 eligible households, a total of 250 
residents in 137 (69%) of the households agreed to participate 
in the investigation. The median number of residents per 
participating household was three (range = 1–9), and a mean 
of two (range = 1–6) residents per household participated in 
the investigation. Median age of the participants (45 years) 
was higher than that of persons who did not participate in the 
investigation but lived in participating households (25 years).
Of the 250 household investigation participants, 70 (28%) 
were laboratory-positive for CHIKV infection, including 12 
(17%) who had current and 58 (83%) who had recent CHIKV 
infection. Of the 70 who were laboratory-positive for CHIKV 
infection, 59 (84%) reported an acute illness in the preceding 
3 months (Table). Of these 59, a total of 56 (95%) reported 
arthralgia, 55 (93%) reported fever, and 53 (90%) reported 
fever and arthralgia. Median duration of illness was 6 days 
TABLE. Characteristics and signs and symptoms of chikungunya cases reported to the Puerto Rico Department of Health or detected through 
household investigations — Puerto Rico, 2014
Characteristic
Reported cases (N = 652)
Recently ill household investigation participants 
(N = 59)
No. (%) No. (%)
Demographics and clinical course
History of recent travel* 31 (5) 1 (1)
Female 344 (53) 27 (46)
Pregnant 8 (1) 1 (2)
Hospitalized 84 (13) 10 (17)
Median days from onset to specimen collection (range) 1 (0–40) 18 (1–60)
Signs and symptoms†
Fever 567 (87) 55 (93)
Arthralgia 512 (79) 56 (95)
Myalgia 518 (79) 48 (81)
Headache 434 (67) 41 (69)
Chills 343 (53) 42 (71)
Rash 263 (40) 32 (54)
Eye pain 282 (43) 18 (31)
Nausea/Vomiting 170 (26) 19 (32)
Abdominal pain 117 (18) 16 (27)
Arthritis§ 97 (15) 29 (49)
Nasal congestion 87 (13) 12 (20)
Cough 92 (14) 13 (22)
Sore throat 101 (15) 14 (24)
Diarrhea 74 (11) 17 (29)
Conjunctivitis 16 (2) 20 (34)
Bleeding manifestations 175 (27) 7 (12)
Minor¶ 172 (26) 7 (12)
Major** 17 (3) 0 (0)
Severe manifestations†† 16 (2) 0 (0)
 * Travel outside of Puerto Rico and the United States in the 14 days before illness onset. 
 † Signs and symptoms were either defined by a clinician for reported cases or were self-reported by household investigation participants. 
 § Five cases reported arthritis in the absence of arthralgia. No investigation participants reported arthritis in the absence of arthralgia.
 ¶ Petechiae, bleeding gums, epistaxis, unspecified mucosal bleeding, and hematuria. 
 ** Purpura/ecchymosis (16 persons), melena (two), hematemesis (two), and vaginal bleeding (one).
 †† Jaundice (nine persons), convulsions (four), effusion (two), encephalitis (one), and hepatomegaly (one).
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(range = 2–21 days). After excluding the index patient for 
each household cluster, 25 (63%) of 40 laboratory-positive 
symptomatic participants sought medical care, of whom five 
(20%) were diagnosed with chikungunya, three (12%) were 
hospitalized, and two (8%) were reported to PRDH as having 
suspected chikungunya.
Public Health Response
In accordance with International Health Regulations, CDC 
was notified after the first locally acquired chikungunya case in 
Puerto Rico was identified. The public health response to the 
impending epidemic focused on raising chikungunya aware-
ness, both among health care providers and the public, and 
implementing syndromic surveillance with laboratory testing 
to enable timely detection of cases. Messaging to health care 
providers focused on the signs and symptoms of chikungunya 
and the need to manage suspected chikungunya patients as 
dengue patients because of their clinical similarity and the 
increased risk for morbidity and mortality if dengue patients 
are not managed appropriately (5,12). Mandatory reporting 
of novel diseases such as chikungunya was already required in 
Puerto Rico; however, supplemental regulations were issued 
requiring reporting of suspected chikungunya cases to PRDH. 
To enable more timely surveillance, a chikungunya sentinel 
surveillance system was initiated in August with nine represen-
tative health facilities selected to monitor epidemiologic trends. 
Discussion
CHIKV was first detected in modern-day Tanzania in 1952–
1953 (13), and later caused outbreaks in countries in the Indian 
Ocean and southern Asia (2). Chikungunya outbreaks typically 
affect a large proportion of the population (e.g., 38%–63%) 
because of high viremia in the host and infected mosquitoes, 
inability to control vector mosquitoes, and lack of preexisting 
protective immunity (2). Some chikungunya patients experi-
ence prolonged morbidity and disability because of joint pain 
that can persist for months or years (14). Fatal chikungunya 
cases are rare (i.e., <0.1% of cases) and are typically associated 
with underlying health conditions or very young or advanced 
age (15). Although there is no specific treatment for either 
dengue or chikungunya, close clinical monitoring of dengue 
patients along with judicious fluid management can reduce 
morbidity and mortality (5,12). 
Passive surveillance for any illness is dependent on ill persons 
seeking medical care, clinician recognition of the illness, and 
reporting of cases to public health authorities. The household 
investigations conducted during the chikungunya epidemic in 
Puerto Rico identified cases that had not been reported, sug-
gesting that the magnitude of the epidemic is larger than sug-
gested by passive surveillance. Because the population of Puerto 
Rico is presumed to be immunologically naïve with respect 
to CHIKV infection and Ae. aegypti mosquitoes are present 
year-round, the high infection rates observed in the household 
investigations were not unexpected. Prior investigations have 
reported rates of asymptomatic CHIKV infection of 3%–28% 
(16,17), similar to the rate observed in this investigation. 
Because of overlapping signs and symptoms, chikungu-
nya and dengue are often difficult to distinguish clinically. 
Therefore, surveillance in areas where both CHIKV and 
DENV are circulating should include laboratory diagnostic 
testing for both illnesses. Although aches and pains are charac-
teristic of both illnesses, arthralgia might be more prominent in 
patients with chikungunya, whereas dengue patients typically 
complain of generalized myalgia and retro-orbital eye pain. 
Similarly, although rash might be present in both dengue and 
chikungunya patients, studies have suggested that it is more 
common and develops earlier in chikungunya patients (18,19). 
Nonetheless, until arthralgia, rash, or other clinical signs or 
What is already known on this topic?
Chikungunya is an emerging infectious disease caused by 
chikungunya virus, which is transmitted via the bite of infected 
Aedes aegypti and Aedes albopictus mosquitoes and was 
introduced into the Western Hemisphere in late 2013. Because 
of clinical similarity with dengue, which is endemic throughout 
the tropics and depends on early identification and proper 
management to reduce morbidity and mortality, patients with 
suspected chikungunya should be managed according to 
recommended strategies for dengue patients.
What is added by this report?
The first locally acquired, laboratory-confirmed chikungunya 
case was detected in Puerto Rico in early May 2014, and 10,201 
suspected cases (282 per 100,000 residents) had been reported 
by August 12. Fever and arthralgia were reported in most 
chikungunya patients, of whom 13% were hospitalized and four 
died. A series of household investigations found that, of 250 
participants, 70 persons (28%) tested positive for current or 
recent chikungunya virus infection, including 59 who reported 
illness within the preceding 3 months. Among 25 participants 
with chikungunya that sought medical care, only two (8%) had 
been reported to health authorities. The identification of 
chikungunya patients through household investigations 
suggests that the actual incidence of chikungunya is higher 
than demonstrated by passive surveillance data.
What are the implications for public health practice?
Improved vigilance and reporting of suspected chikungunya cases 
by health care providers can help health authorities estimate the 
health burden of chikungunya in Puerto Rico and help mobilize the 
resources needed to respond to the epidemic and direct them to 
affected areas. The chikungunya epidemic is expected to continue 
until a critical threshold of the population is no longer susceptible 
to infection, until which time early and accurate identification of 
dengue patients will remain a challenge.
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symptoms have been shown to clearly differentiate patients 
with chikungunya from those with dengue, the introduction 
of chikungunya to the Americas heightens the clinical chal-
lenge of ensuring optimal management of dengue patients†† 
(i.e., hospitalization of patients with warning signs of severe 
dengue [e.g., persistent vomiting, severe abdominal pain] or 
other severe manifestations, and providing outpatients with 
appropriate anticipatory guidance). Because persons with 
suspected chikungunya might have dengue, nonsteroidal 
anti-inflammatory drugs (e.g., aspirin and ibuprofen) should 
be avoided and fever and pain should be managed with acet-
aminophen until there is a clear diagnosis and the patient is 
free of warning signs.
Although severe disease manifestations were uncommon 
among CHIKV-infected persons in Puerto Rico, clinicians 
should be aware of severe manifestations that have been pre-
viously associated with CHIKV infection (e.g., encephalitis 
and vesiculobullous skin lesions). Future investigations should 
describe the incidence and clinical course of patients in the 
Americas with severe manifestations of CHIKV infection, 
and verify previously identified risk factors for developing 
them (e.g., hypertension, underlying respiratory or cardiac 
conditions, and age ≥40 years) (15). Similarly, additional 
investigation is needed to determine the relative contribution 
of CHIKV infection and underlying medical conditions in 
the four fatal cases thus far reported. Finally, because CHIKV 
infection has been associated with persistent joint pain for 
months after the initial illness (14), additional investigation 
in the Americas is needed to quantitate disability caused by 
chikungunya-associated persistent joint pain.
The findings in this report are subject to at least two limita-
tions. First, because of the large volume of cases reported to 
PRDH, not all specimens were tested. Instead, priority was 
assigned to specimens from hospitalized patients and munici-
palities that had not yet identified a laboratory-positive case. 
Thus, age- and municipality-specific incidence of chikungunya 
could not be accurately calculated. Second, household inves-
tigations were conducted during the daytime on weekdays, 
when children and working-age adults might not be available. 
Older persons might spend more hours at home during the day, 
when Ae. aegypti mosquitoes are most active, and might also 
have preexisting arthritis or other health conditions that might 
be exacerbated following CHIKV infection. Consequently, 
the rates of CHIKV infection and the associated symptoms 
identified through household investigations might not be 
representative of the population.
Because of the high volume of reported chikungunya cases, 
a network of sentinel chikungunya surveillance sites was estab-
lished across Puerto Rico to better monitor the progression 
and trends of the chikungunya epidemic and the concurrent 
incidence of dengue. Clinical education seminars have been 
conducted throughout Puerto Rico to improve provider aware-
ness of chikungunya, including the need to manage patients 
with suspected chikungunya the same way that dengue patients 
are managed. Messages to the public have emphasized the 
need to dispose of or empty water containers that can serve as 
mosquito breeding sites (e.g., refuse, discarded tires, and flower 
pots), and recommended seeking care early for acute febrile 
illness and managing fever and pain with acetaminophen. 
The chikungunya epidemic is expected to continue until a 
critical proportion of the population is no longer susceptible 
to infection. Forecasting the duration of the epidemic might 
be achieved through serologic surveys to monitor increases in 
population immunity.
Residents of and travelers to areas of the tropics with ongoing 
CHIKV and DENV transmission should employ mosquito 
avoidance strategies to prevent illness. Such strategies should 
include use of mosquito repellent, wearing long sleeves and 
pants, and staying in residences with air conditioning and 
screens on doors and windows. Additional information on 
chikungunya, including up-to-date case counts and affected 
areas, is available at www.cdc.gov/chikungunya.
 1Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic 
Infectious Diseases, CDC; 2Office of Epidemiology, Puerto Rico Department 
of Health; 3Division of Environmental Hazards and Health Effects, National 
Center for Environmental Health, CDC; 4Epidemic Intelligence Service, CDC; 
5Influenza Division, National Center for Immunization and Respiratory 
Diseases, CDC; 6Division of Global Health Protection, Center for Global 
Health, CDC (Corresponding author: Tyler M. Sharp, tsharp@cdc.gov, 
787-706-2399)
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